Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.84% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTFATE THERAPEUTICS INC's latest supported as-filed period reports revenue of $2.1M, 9.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.84% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -1123.92% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 9.18% · CORE
Level · gp.fundamentals.operating_margin
Raw value -1495.39% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 1171.33% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 168.97% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -21.4% from the comparable as-filed period.
Net income changed +11.5% from the comparable as-filed period.
Operating income changed +15.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
FATE · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-347988SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-347984SEC ↗4Aug 5, 2026Period Aug 4, 20260001193125-26-335019SEC ↗4Aug 5, 2026Period Aug 4, 20260001193125-26-335007SEC ↗4Jun 15, 2026Period Jun 12, 20260001104659-26-074130SEC ↗4Jun 15, 2026Period Jun 12, 20260001104659-26-074126SEC ↗4Jun 15, 2026Period Jun 12, 20260001193125-26-271090SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 4, 2026Filed Aug 5, 2026 | TAHL CINDYSee Remarks | Open Market SaleDirect | 38,800 | $2 | $95,405 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +44315 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed -11.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Revenue changed +9.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed -50.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-271088